Discovery & Development Europe 2025

01 - 02 July 2025 | Basel, Switzerland

Pushing traditional boundaries in pharmaceutical science by accelerating the discovery & development of novel therapeutics

Overview Discovery & Development Formulation & Delivery

Explore Discovery & Development Europe 2025: Guiding Biopharma From Target Identification To Clinical Candidate

Connect & collaborate with 1000+ leaders in biology and chemistry at the renowned Discovery & Development Summit in Basel, where we provide a platform to help you make informed pipeline decisions in early R&D & accelerate the route from target identification to novel clinical candidate, ultimately increasing the number of life-saving treatments for those with critical illnesses.

Together with Formulation & Delivery, benefit from an event supporting you to identify potential formulation & delivery bottlenecks and issues before they arise and promoting collaboration to ensure the development of optimised drug products.

Discovery Europe 2025

Across 12 specialized topic tracks and 100+ presentations, our congress touches on all aspects of the drug development journey, regardless of disease area or modality. Hear how experts are utilizing the latest technologies for target identification & validation and exactly how these are being translated into the preclinical phase. Gain exclusive insights into the current innovation in the space with novel biologic & small molecule targets, including ADCs, cell and gene therapies, PROTACs, molecular glues & more!

Packed with interactivity, networking and engaging talks, our Discovery Europe event will equip you with the knowledge & connections needed to keep ahead of the trends & make rapid advancements within your R&D.

 

Agenda at a Glance


Day 1

  • Track 1: Target Identification & Validation
  • Track 2: Medicinal & Computational Chemistry
  • Track 3: Translating Targets Into Therapies
  • Track 4: Novel Large Molecule Targets
  • Track 5: Targeting Neurodegeneration & Age-Related Disease
  • Track 6: Lab Digitalization & Connectivity

Day 2

  • Track 1: Functional Genomics & Cellular Technologies
  • Track 2: Hit Identification & Screening
  • Track 3: DMPK, Pharmacology & Safety
  • Track 4: Novel Small Molecule Targets
  • Track 5: Targeting Neuroimmunology & Neuroinflammation
  • Track 6: Implementing Automation & Robotics

Formulation & Drug Delivery Congress

Join over 1000 cross-industry experts at Formulation & Delivery 2025 connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in pharmaceutical drugs formulation, drug delivery, RNA development & Peptides and Oligonucleotide design. 

Across two days our programme will include 8 specialised topic areas diving into specific developments within the industry, from formulation strategies for cell and gene therapies, PROTACs and Nanotechnology to the latest advancements in enhancing bioavailability.

Our Formulation & Delivery event will be co-located with Discovery Europe 2025 in Basel. Enjoy the collaboration as we support your engagement with discovery and formulation colleagues to ensure a smoother development of optimised drug products. 

Leading expert scientists working across formulation, drug delivery, bioanalysis, developability, and manufacturing science & technologies, representing global pharmaceutical organisations, leading biotechnology companies and internationally renowned academic institutions. 

Over 50 technical presentations and case studies focused on the critical topics in AI for automated formulations, enhanced drug delivery through vaccines, PROTAC, and exosomes, as well as an exploration of sustainable drug development.

Agenda at a Glance


Day One

  • Track 1: Small Molecule Formulation
  • Track 2: Large Molecule Delivery
  • Track 3: Preformulation Studies

Day Two

  • Track 1: Large Molecule Formulation
  • Track 2: Small Molecule Drug Delivery
  • Track 3: Process Chemistry & Pharmaceutical Materials Analysis
f9d83b55-ff87-4538-a4e2-f67b63da4765-2-5668375logo-Axion-Logo_Tagline_2022

 

Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.


Regional Sales Director
AxionBio

5a563b71-261f-4b78-a13b-5b4890a6b41d-2-5668375logo-Copy-of-Arctoris-blue-logo-1-Transparent

 

Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development
Arctoris

Novalix Logo

 

The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.


Pharmacology Associate Director
Novalix

novartis-logo

 

This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.


Senior Principal Scientist

Novartis

What to Expect

1000

leading pharma, biotech & academic delegates

55
hours of presentations, discussions & interactive content
9
hours of networking breaks, including speed networking & refreshments
240
pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership
What to Expect Global Technological Showcase
What to Expect Networking Emphasis
What to Expect Innovative Poster Displays

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Introducing our 2025 Summit Theme: Innovation at Speed

Today’s biopharma leaders must balance two priorities – acceleration (reducing the time from target ID to clinical candidate without compromising safety & efficacy) and innovation (bringing a consistent pipeline of novel drugs to market for difficult to treat diseases). This is at the heart of the 2025 programme, where we explore the newest methods, tools and strategies that will support scientists developing innovative therapeutics at speed. Expect:

  • Scientific & technical case studies highlighting best practice in every stage of the early R&D pipeline
  • Spotlights on novel targets making a splash – from small molecules beyond RO5 to innovative biologics
  • Deep dives on disease areas with the most unmet need, including a spotlight on targeting Neuroscience
  • Practical examples on how to implement automation & AI within R&D to improve lab productivity

Companies Represented Include

Introducing the Start-Up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs. 

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

There are two options, based on the size of your organisation with prices starting from €1800. 

For further information and to get started submit the application form below.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.


To be eligible for inclusion, you must meet the following criteria:

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding


What you will receive:

  • 1 full conference pass
  • 10-minute pitch on the Start-Up Stage
  • 1x1m space in Start-Up Zone for own partnering meetings; cocktail table provided, start-up to bring 1x pull-up banner
  • Logo featured on website & event platform as a participating start-up
  • Ability to arrange 1:1 meetings via the congress app

Biotech Innovation & Collaboration

Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Discovery Research & Development

Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers 
  • Discovering new investment opportunities with pharma 
  • Learning about the latest industry trends & challenges  
  • Keeping updated with new innovations and technology solutions 
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The Discovery Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist. 

Please submit your poster presentation by no later than 20th December 2024 in the below category: 

  • Emerging Technologies  
  • Biomarkers in Therapeutics  
  • Biomarkers in Diagnostics  
  • Biomarkers in Clinical Trials & Precision Medicine  
  • Omics-Based Biomarker Discovery
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 20th December 2024 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact help@oxfordglobal.com

Meet Our Expert Speakers

Discovery & Development Europe 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Dan Hardy
Chief Executive Officer,
Microsol Ltd
Davide Gianni
Senior Director,
AstraZeneca
Emma Mead
Chief Scientific Officer, Oxford Drug Discovery Institute,
University of Oxford
Heinrich Haas
Chief Technology Officer,
Neovacs
Joël Richard
Chief Development Officer,
Enterome
Johan Luthman
Executive Vice President of Research & Development,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Rekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Sorina Morar-Mitrica
Associate Director Science & Technology,
Novartis
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Stephen Pham
Senior Vice President,
Avalyn Pharma Inc.
Yogeshvar Kalia
Prof,
University of Geneva
Afzal R Mohammed
Professor,
Aston University
Andreas Gryczke
Director, Process Engineering,
AbbVie
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Arne Skerra
Professor,
Technische Universität München
Chuang Kee Ong
Director Data Product,
GSK
Farshad Ramazani
Senior Expert Science & Technology,
Novartis Pharma
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
James Dale
Director of Drug Discovery,
PharmEnable Therapeutics
Jens Twellmeyer
Associate Director Science & Technology,
Novartis AG
Jessica Yu
Senior Scientist,
AstraZeneca
Jörg Berghausen
Associate Director,
Novartis
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Morten Grunnet
Vice President, Head of Neuroscience,
Lundbeck
Poppy Winlow
Senior Research Scientist,
AstraZeneca
Preethi Soundarya Sathyamurthi
Senior Scientist,
GSK
Rainer Wilcken
Director, Computational Chemistry,
Flare Therapeutics Inc
Rajaa Sukhun
Senior Director of Research DMPK,
Cytokinetics
Ramesh Kashi
Consultant,
Self Employed
Raul Rodriguez
Vice President,
Woxsen University
Sabine Kuratli
CMC Lead,
CEPI
Sandor Batkai
Co-founder, Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Simone Vecchi
Associate Director - Drug Product Development Scientific Integrator,
Johnson & Johnson Innovative Medicine
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Ulrich Betz
Vice President Innovation Department Head Innovation & Entrepreneurship Incubator,
Merck
Varun Kushwah
Principal Scientist,
RCPE
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics Ltd
Vineeta Tripathi
Chief Executive Officer,
Vitarka Therapeutics
Yi Sun
Associate Professor,
Technical University of Denmark

Interested in Sponsoring?

Our extensive and engaged community extends across large, mid-size and emerging companies within the pharma and biotech space, with a dedicated audience spanning a range of specialisms. Whether you have content to share, are looking for ways to enhance your brand visibility or would like to increase engagement with prospective customers, Oxford Global can offer valuable access to your target demographic through our range of event & content services.

Latest Resources

AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs

Intrepid Labs demonstrates how its self-driving lab uses ML and robotics to advance drug formulation.

2024 Nobel Prize in Chemistry Awarded to Pioneering Advances in Protein Design and Structure Prediction

The 2024 Nobel Prize in Chemistry was awarded to three scientists working on computational protein design and protein structure prediction.

Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years

According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults.

The Power of Philanthropy in Transforming Pancreatic Cancer Research

The Stephenson Prize for innovation in pancreatic cancer research was launched alongside a $150 million gift to City of Hope.

The Role of Immuno-Organoids in Drug Discovery And Disease Modelling

A study conducted by Roche demonstrates how to create new human models with tissue-integrated immune cells.

Strategic Acquisition: Otsuka Pharmaceutical to Pay Up to $1.1 billion to Acquire Jnana Therapeutics' Drug Discovery Platform

The Japanese healthcare company Otsuka Pharmaceutical will acquire clinical-stage biotech Jnana Therapeutics.

Plan Your Visit

Full details regarding accommodation, travel directions, health and safety, and other logistical information for the event will be added here in the coming months.

Register Your Interest

Submit your details and a member of our team will be in touch